As Ranbaxy Founders Exit, Daiichi Sankyo Assumes Complete Control; New Management Expects To Resolve U.S. FDA Issue
This article was originally published in The Pink Sheet Daily
Executive Summary
"We will look at the future more than the past. Daiichi has already sent its plans to the FDA, and we are waiting for a response from the regulators," Atul Sobti, the company's new CEO, said.
You may also be interested in...
Ranbaxy Records Worst Ever Quarterly Loss On Forex Contracts, FDA Action; Rival Cipla Is Going Strong
MUMBAI - Signs of a deepening financial crisis became visible at India's largest drug maker Ranbaxy as it announced its first quarter results with a worst ever recorded quarterly loss of $153 million (761 crore rupees) on sales of $313 million, which fell 4 percent as compared to the same quarter last year
Ranbaxy In Bear Grip As Sales Slip In U.S. After FDA Restrictions
MUMBAI - India's Ranbaxy, now part of Japanese drug maker Daiichi Sankyo, has witnessed a sharp drop in its market share in the U.S., having lost as much as 40 percent in sales since last August. The drop in prescriptions is at a staggering 50 percent as compared to the company's February 2008 sales data. According to a Deutsche Bank report, this indicates that Ranbaxy will lose further prescriptions and hence revenues
U.S. FDA Nails Ranbaxy On Charges Of Falsifying Data; Halts All Application Reviews From Paonta Sahib Plant
MUMBAI - India's largest drug maker Ranbaxy received a body blow after the U.S. Food and Drug Administration initiated a new regulatory action against the company's Paonta Sahib-based manufacturing plant in India. The drug regulator halted review of drug applications from the manufacturing plant due to evidence of falsified data and invoked the Application Integrity Policy